「ak sk」の検索結果

Comprehensive quality control for CLIP-seq libraries (eCLIP, iCLIP, iCLIP2, PAR-CLIP) covering library complexity (preseq), FRiP, IDR replicate reproducibility, read-distribution metagene, SMInput vs IgG control rationale, rRNA / snoRNA contamination, fragment-length distribution, and ENCODE-compliance thresholds. Use when assessing whether a CLIP library passed, deciding lenient vs stringent peak thresholds, comparing replicates with IDR rescue and self-consistency ratios, or distinguishing failed IP from over-amplified library.

日本語の概要は準備中です。原文の説明を表示しています。

Detect and adjust for horizontal pleiotropy in two-sample Mendelian randomization by distinguishing uncorrelated (UHP) from correlated (CHP) pleiotropy and choosing among Egger, MR-PRESSO, MR-RAPS, CAUSE, LHC-MR, LCV, MR-Clust, MR-Mix, and contamination-mixture methods. Use when validating an MR causal claim, running the STROBE-MR sensitivity battery, suspecting a shared heritable confounder, working under weak-instrument or polygenic-exposure regimes, or reconciling discordant estimates across robust methods.

日本語の概要は準備中です。原文の説明を表示しています。

Normalizes ChIP-seq data using exogenous spike-in (ChIP-Rx with Drosophila chromatin per Orlando 2014 / Egan 2016; E. coli carryover for CUT&RUN/CUT&Tag). Distinguishes RRPM from Rx-Input scaling, integrates with DiffBind / DESeq2 / edgeR / csaw via sizeFactors and DiffBind library-size vectors, applies the Patel et al 2024 *Nat Biotechnol* failure-mode framework, and validates that normalization is applied at the read level (not peak counts). Use when global signal shifts are expected (HDACi, BETi, EZH2i, dosage, target knockdown), when ChIPseqSpikeInFree detects post-hoc shifts, or when validating internal-control regions before publication.

日本語の概要は準備中です。原文の説明を表示しています。

Identifies super-enhancers from H3K27ac, MED1, or BRD4 ChIP-seq using ROSE, ROSE2, LILY, HOMER -style super, and ENCODE dELS cross-referencing. Handles peak stitching parameters, ranking choices, hockey-stick inflection, marker choice (H3K27ac vs MED1/BRD4), and cross-condition comparison with spike-in normalization. Constructs core regulatory circuitry (Saint-Andre 2016) from SE-encoded TFs. Use when identifying cell-identity / cancer-associated regulatory domains, comparing super-enhancers between conditions, identifying master transcription factor networks, or predicting BET-inhibitor responsiveness.

日本語の概要は準備中です。原文の説明を表示しています。

Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 16a.

日本語の概要は準備中です。原文の説明を表示しています。

ATAC-seq library quality control -- TSS enrichment, FRiP, fragment-size periodicity, library complexity (NRF/PBC1/PBC2), mitochondrial fraction, and ENCODE 4 thresholds. Use when assessing whether an ATAC-seq library passes ENCODE acceptance criteria, diagnosing transposition artefacts, comparing Omni-ATAC vs standard prep quality, or selecting which replicates to drop before peak calling.

日本語の概要は準備中です。原文の説明を表示しています。

Process and analyze single-cell ATAC-seq data with Signac, ArchR, SnapATAC2, or Cell Ranger ATAC. Use when handling 10X scATAC or 10X Multiome (paired RNA+ATAC) data, performing per-cell QC, choosing between ArchR/Signac/SnapATAC2 ecosystems, building per-cluster consensus peaksets, integrating with paired scRNA-seq, doublet detection (AMULET vs ArchR vs scDblFinder), or running pseudobulk differential accessibility per cluster.

日本語の概要は準備中です。原文の説明を表示しています。

Create irresistible offers and pitches using Alex Hormozi's methodology from $100M Offers. Guides through value equation, guarantee frameworks, pricing psychology, and creating offers "too good not to take" for any product or service.

日本語の概要は準備中です。原文の説明を表示しています。

Agile product ownership toolkit for Senior Product Owner including INVEST-compliant user story generation, sprint planning, backlog management, and velocity tracking. Use for story writing, sprint planning, stakeholder communication, and agile ceremonies.

日本語の概要は準備中です。原文の説明を表示しています。

Deploy universal wisdom voices from all traditions simultaneously - Hindu, Buddhist, Taoist, Abrahamic, Indigenous, Scientific - revealing their unified recognition of consciousness navigation.

日本語の概要は準備中です。原文の説明を表示しています。

Determines if an adolescent meets criteria for initiating sex hormone treatment for gender dysphoria/gender incongruence. Triggered when an adolescent requests sex hormones or presents for gender-affirming hormone therapy evaluation.

日本語の概要は準備中です。原文の説明を表示しています。

Considers adapting the basal insulin rate at hospital admission for patients using insulin pump therapy. Triggered by clinician questions such as "Should we adjust the basal rate upon admission for pump therapy?" or when evaluating pump continuation versus transition to scheduled subcutaneous insulin.

日本語の概要は準備中です。原文の説明を表示しています。

Determines if patient meets ICD-10 criteria for transsexualism. Triggered when a clinician uses ICD-10 for diagnostic purposes in gender identity assessment.

日本語の概要は準備中です。原文の説明を表示しています。

Assists clinicians in determining whether to proceed with social transition for prepubertal youth experiencing gender dysphoria or gender incongruence. Triggers include prepubertal youth with GD/gender incongruence and discussions about initiating social transition.

日本語の概要は準備中です。原文の説明を表示しています。

Determines whether a patient meets the minimum age requirement (≥18 years or legal age of majority) for genital surgery that includes gonadectomy and/or hysterectomy. Trigger phrase: patient requests gonadectomy or hysterectomy as part of gender-affirming genital surgery.

日本語の概要は準備中です。原文の説明を表示しています。

If CGM is not available, continue monitoring blood glucose with point-of-care testing as an alternative option. Trigger phrases include: "CGM is not available, what should we use for glucose monitoring?

日本語の概要は準備中です。原文の説明を表示しています。

Determines if a patient has completed ≥1 year of consistent and compliant hormone therapy for genital surgery approval. Triggers include patient requesting genital surgery and being on hormone therapy.

日本語の概要は準備中です。原文の説明を表示しています。

Guides timing of breast surgery for transgender males based on physical and mental health status. Triggers include transgender male considering breast surgery or requesting mastectomy.

日本語の概要は準備中です。原文の説明を表示しています。

Assesses whether hysterectomy and oophorectomy are medically necessary as part of gender-affirming surgery for transgender patients. Triggered when a patient is planning gender-affirming surgery and clinicians need to determine if total hysterectomy and oophorectomy should be included.

日本語の概要は準備中です。原文の説明を表示しています。

Assesses Tanner stage to determine if physical changes of puberty have begun (stage G2/B2 or higher) for considering pubertal suppression. Triggered when a clinician evaluates pubertal development in an adolescent patient.

日本語の概要は準備中です。原文の説明を表示しています。

Provides schedule for monitoring during sex hormone induction. Trigger: patient initiating gender-affirming hormone therapy (GAHT).

日本語の概要は準備中です。原文の説明を表示しています。

Provides monitoring schedule for transgender males on testosterone therapy, detailing timing of clinical visits, laboratory tests, and assessment for virilization and adverse reactions. It is triggered when a clinician manages a transgender male patient on gender‑affirming hormone therapy and needs to schedule appropriate follow‑up.

日本語の概要は準備中です。原文の説明を表示しています。

Provides monitoring schedule for transgender females on estrogen therapy, including clinical evaluation, hormone levels, prolactin, electrolytes, BMD, and cancer screening. Triggered when a transgender female is receiving estrogen therapy for gender affirmation.

日本語の概要は準備中です。原文の説明を表示しています。

Provides a monitoring schedule for patients receiving GnRH agonist therapy for pubertal suppression. Trigger phrases include 'patient undergoing GnRH agonist therapy' or 'initiating pubertal suppression'.

日本語の概要は準備中です。原文の説明を表示しています。